These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18457612)

  • 21. Osteoarthritis: a review of treatment options.
    Seed SM; Dunican KC; Lynch AM
    Geriatrics; 2009 Oct; 64(10):20-9. PubMed ID: 20726384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management.
    Shah S; Mehta V
    Postgrad Med J; 2012 Feb; 88(1036):73-8. PubMed ID: 22052884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of analgesics in the management of osteoarthritis pain.
    Brandt KD
    Am J Ther; 2000 Mar; 7(2):75-90. PubMed ID: 11319576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current state of therapy for pain and inflammation.
    Abramson SB; Weaver AL
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S1-6. PubMed ID: 16168076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
    Rannou F; Pelletier JP; Martel-Pelletier J
    Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S18-21. PubMed ID: 26806189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical considerations for the pharmacologic management of osteoarthritis.
    Altman RD
    Am J Manag Care; 2009 Sep; 15(8 Suppl):S236-43. PubMed ID: 19817510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.
    Huang WN; Tso TK
    Bosn J Basic Med Sci; 2018 Feb; 18(1):87-94. PubMed ID: 28954205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complexities in the pharmacologic management of osteoarthritis pain.
    McCarberg B; Tenzer P
    Curr Med Res Opin; 2013 May; 29(5):539-48. PubMed ID: 23489409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug therapy of arthrosis].
    Steinmeyer J
    Orthopade; 2001 Nov; 30(11):856-65. PubMed ID: 11766630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valdecoxib: a review.
    Chavez ML; DeKorte CJ
    Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
    Pellissier JM; Straus WL; Watson DJ; Kong SX; Harper SE
    Clin Ther; 2001 Jul; 23(7):1061-79. PubMed ID: 11519771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
    Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis.
    Jobanputra P; Nuki G
    Curr Opin Rheumatol; 1994 Jul; 6(4):433-9. PubMed ID: 8068516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.